Gold Rises Sharply; Lyra Therapeutics Shares Plunge

Market Performance - U.S. stocks showed mixed trading, with the Nasdaq Composite gaining over 50 points, while the Dow decreased by 0.19% to 49,411.94 and the S&P 500 rose by 0.04% to 6,969.38 [1] - Consumer staples shares increased by 1%, while financial stocks dipped by 1.1% [1] Commodities - Oil prices fell by 0.7% to $58.72, while gold prices rose by 2.5% to $4,612.70 [5] - Silver increased by 7.1% to $84.970, and copper rose by 1.1% to $5.9655 [5] European Markets - European shares were higher, with the eurozone's STOXX 600 gaining 0.21%, Spain's IBEX 35 Index rising 0.12%, and London's FTSE 100 increasing by 0.16% [6] Asian Markets - Asian markets closed higher, with Hong Kong's Hang Seng Index gaining 1.44%, China's Shanghai Composite rising 1.09%, and India's BSE Sensex increasing by 0.36% [7] Company Updates - Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77, reporting preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year [9] - Rxsight Inc (NASDAQ:RXST) shares increased by 12% to $9.88, announcing preliminary fourth-quarter revenue of $32.6 million [9] - SunOpta Inc (NASDAQ:STKL) shares rose by 18% to $4.38 after raising its FY2025 sales guidance [9] - Atara Biotherapeutics Inc (NASDAQ:ATRA) shares dropped 53% to $6.41 following an FDA Complete Response Letter citing clinical trial adequacy concerns [9] - Lyra Therapeutics Inc (NASDAQ:LYRA) shares fell 51% to $1.84 after announcing plans to suspend development of its lead product candidate and implement workforce reductions [9] - Lexeo Therapeutics Inc (NASDAQ:LXEO) shares decreased by 28% to $7.60 after announcing interim Phase I/II data for LX2020 [9]